Ranbaxy Adds India Plant To Make Generic Lipitor As U.S. Exclusivity Ends
This article was originally published in PharmAsia News
Daiichi Sankyo’s Ranbaxy Laboratories has begun producing its generic of Pfizer’s Lipitor (atorvastatin) anti-cholesterol drug at a plant in India in addition to a U.S. factory as it faces the end of its six months of generic exclusivity rights.
You may also be interested in...
With some studies about to finish and others on clinical hold, the coronavirus vaccine field approaches an infection point as the US FDA prepares for its first advisory committee on the topic. Our charts and graphics offer a quick look at what stands where.
Funds will be used to expand European sales of the CE-marked Lenire device, scale-up manufacturing and progress US regulatory and reimbursement plans.
RB CEO Laxman Narasimhan sees the potential for the company to establish a global supplements business built on the successes it has enjoyed in the US and China. The comments came as RB reported solid growth in the third quarter, despite struggles for its OTC brands.